Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
McKinsey
Chubb
Cipla
US Department of Justice

Generated: April 22, 2019

DrugPatentWatch Database Preview

Litigation Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

« Back to Dashboard

ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Docket ➤ Sign Up Date Filed 2011-02-09
Court District Court, D. New Jersey Date Terminated 2013-06-03
Cause 35:145 Patent Infringement Assigned To Joel A. Pisano
Jury Demand None Referred To Magistrate Judge Tonianne J. B
Parties AKTIEBOLAGET HASSLE; ASTRAZENECA AB; ASTRAZENECA LP; HANMI FINE CHEMICAL CO., LTD; HANMI HOLDINGS CO., LTD.; HANMI PHARMACEUTICAL CO., LTD.; HANMI USA, INC.; KBI INC.; KBI-E INC.
Patents 4,255,431; 4,508,905; 4,738,974; 5,714,504; 5,877,192; 6,143,771
Attorneys ALLYN ZISSEL LITE; ARNOLD B. CALMANN; JEFFREY S. SOOS; JOHN EDMUND FLAHERTY; JONATHAN M.H. SHORT; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS
Link to Docket External link to docket
Small Molecule Drugs cited in ASTRAZENECA AB v. HANMI USA, INC.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-10-11 101 Orange Book patents for Nexium®, including the ’504 patent and U.S. Patent No. 5,877,192 on which AstraZeneca… of U.S. Patent No. 5,714,504 (“the ’504 patent” (D.I. 86-2))1 in this Hatch-Waxman patent infringement…described in patents or published patent applications filed and published after the ’504 patent was filed…its own patent (Ex. 63). 1 This motion addresses the asserted claims of the ‘504 patent – claims…omeprazole. Yet nowhere in the ‘504 patent specification (or the original patent application resulting in the External link to document
2011-10-31 124 AstraZeneca patents: U.S. Patent No. 5,714,504 (“the '504 patent”) and U.S. Patent No. 5,877,192 ("…description in the patent of hydrated forms of alkaline salts of esomeprazole, and that the patent does not enable…quot;the '192 patent"). In claim construction proceedings in an earlier case, AstraZeneca A.B.,…in the claims of both the '504 and '192 patents. Claim construction proceedings in the present…scheduling disputes First, claim 1 of the '504 patent recites a pharmaceutical formulation comprising External link to document
2011-11-07 132 of the patents-in-suit – U.S. Patents 5,714,504 (“the ’504 patent,” D.I. 86-2) and 5,877,192 (“the ‘…although the ‘192 patent purports to be a continuation-in-part (“CIP”) of the ‘504 patent, the two have …the patent specification, the patentee’s definition controls.”). The specification of the patent “acts…subject matter of the ‘504 patent. (D.I. 86-2.) Thus, the scope of the patent is limited from the start…U.S. Patent 6,875,872 (Ex. 2), which has the same specification as the ‘504 patent. External link to document
2011-11-07 133 its U.S. counterpart, U.S. Patent No. 4,738,974, are AstraZeneca patents that discuss “alkaline salts…s”) U.S. Patents Nos. 5,714,504 (the “ ’504” patent) and 5,877,192 (the “ ’192” patent), which cover…and ’192 patents are at issue in this litigation. The asserted claims of the ’504 patent (claims 1… “alkaline salt” in the ’504 patent. 64. The ’192 patent states in column 1, before the…. U.S. Patent Application No. 08/376,512 is the application that issued as the ’504 patent. In my External link to document
2011-12-03 156 application”) that issued as U.S. Patent No. 5,877,192 (the “‘192 patent”). I have also been asked to… US Patent 5,877,192 and file history 8. AstraZeneca’s COMPLAINT for Patent Infringement…FINE CHEMICAL CO., LTD. AND PATENT NO. 5,877,192 AND HANMI HOLDINGS CO., LTD., … Summary Judgment No. 2: Invalidity of USP 5,877,192 - Claims 12, 19, 21-22," dated October 11…No. 2: Invalidity of USP 5,877,192 - Claims 12, 19, 21-22 2. External link to document
2011-12-03 159 ofUS Patent 5,877,192. 4. Attached as Exhibit B is a true and correct copy of US Patent 5,714,504…comparison of the disclosures of the '504 Patent, the '818 Patent and the Swedish '830 Application…of Commerce, Patent and Trademark Office Revision of the Materiality to Patentability Standard for the…Attached as Exhibit Cis a true and correct copy of US Patent 5,693,818. 6. Attached as Exhibit D…Attached as Exhibit E is a true and correct copy of US Patent Application Publication 2007/0093533 AI. External link to document
2011-12-30 167 . 10); • AstraZeneca’s U.S. Patent No. 6,143,771 (Ex. 3)3 uses the term “solid state” to …the ’504 patent specification. (D.I. 155, SOF ¶14.) AstraZeneca concedes that the ’504 patent does not…Claim 11). The ’771 patent, whose specification is identical to the ’504 patent, thus used “solid state…504 Patent with Ex. 3). By AstraZeneca’s own actions -- on the intrinsic record of the ’504 patent -- …As shown on the face of the ’771 patent, it is part of the ’504 patent's intrinsic record, since AstraZeneca External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
Merck
Boehringer Ingelheim
Express Scripts
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.